Caren van Roekel

143 Mode of progression after radioembolization in colorectal cancer patients TABLE 1. Baseline and treatment characteristics (continued) Characteristic N (%) or median with range 90 Y-resin 90 Y-glass 166 Ho No extrahepatic disease Extrahepatic disease at baseline Total Unknown 12 (26) 4 (20) 1 (4) 7 (15) 10 (24) 17 (19) Primary tumor in situ Yes 1 (2) 4 (20) 2 (8) 2 (4) 5 (12) 7 (8) No 45 (98) 16 (80) 22 (92) 46 (96) 37 (88) 83 (92) Extrahepatic disease (all metastases) None 27 (59) 9 (45) 10 (42) 48 (100) 0 (0) 48 (53) Lymph node metastases 12 (26) 8 (40) 7 (29) - 25 (60) 25 (28) Lung metastases 8 (17) 2 (10) 7 (29) - 17 (40) 17 (19) Abdominal wall metastases 1 (2) 0 (0) 0 (0) - 1 (2) 1 (1) Spleen metastases 0 (0) 0 (0) 2 (8) - 1 (2) 1 (1) Adrenal gland metastases 0 (0) 2 (10) 0 (0) - 2 (5) 2 (2) Peritoneal metastases 1 (2) 0 (0) 2 (8) - 3 (7) 3 (3) Type of radioembolization Whole-liver 41 (89) 12 (60) 20 (83) 38 (79) 35 (83) 73 (81) Lobar 5 (11) 8 (40) 4 (17) 10 (21) 7 (17) 17 (19) Injected activity (MBq) 1526 (636-2320) 2037 (711-6277) 6565 (2213-11627) 1882 (636-11164) 1992 (680-11627) Not applicable Lungshunt (%) 5 (0.1-17) 2.3 (1-26) 4.6 (0.3-16) 4.5 (0.1-17) 3.4 (0.8-26) 4 (0.1-26) 5